David Loomis Sells 1,016 Shares of Arvinas (NASDAQ:ARVN) Stock

Arvinas, Inc. (NASDAQ:ARVN) CAO David Loomis sold 1,016 shares of the stock in a transaction on Friday, February 13th. The shares were sold at an average price of $11.89, for a total value of $12,080.24. Following the sale, the chief accounting officer directly owned 30,800 shares in the company, valued at $366,212. This trade represents a 3.19% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Arvinas Stock Up 4.8%

Arvinas stock opened at $12.39 on Friday. The company has a market capitalization of $795.69 million, a price-to-earnings ratio of -15.30 and a beta of 1.88. The stock has a 50-day moving average price of $12.38 and a 200 day moving average price of $10.35. Arvinas, Inc. has a 52 week low of $5.90 and a 52 week high of $19.15.

Institutional Trading of Arvinas

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Tower Research Capital LLC TRC increased its position in shares of Arvinas by 491.4% during the second quarter. Tower Research Capital LLC TRC now owns 5,819 shares of the company’s stock valued at $43,000 after acquiring an additional 4,835 shares during the last quarter. Canada Pension Plan Investment Board raised its holdings in Arvinas by 109.4% during the second quarter. Canada Pension Plan Investment Board now owns 6,700 shares of the company’s stock worth $49,000 after purchasing an additional 3,500 shares in the last quarter. State of Wyoming acquired a new stake in shares of Arvinas during the third quarter worth about $68,000. Virtus Investment Advisers LLC increased its stake in Arvinas by 49.3% in the 2nd quarter. Virtus Investment Advisers LLC now owns 12,422 shares of the company’s stock valued at $91,000 after buying an additional 4,104 shares during the period. Finally, Aster Capital Management DIFC Ltd purchased a new position in Arvinas during the 3rd quarter worth $92,000. 95.19% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on ARVN shares. Wedbush restated a “neutral” rating and issued a $9.00 price target on shares of Arvinas in a research report on Thursday, November 6th. Barclays boosted their price objective on Arvinas from $16.00 to $18.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 17th. Wall Street Zen downgraded Arvinas from a “hold” rating to a “sell” rating in a research note on Saturday, February 14th. Stephens boosted their price target on shares of Arvinas from $14.00 to $15.00 and gave the company an “overweight” rating in a research report on Monday, November 10th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Arvinas in a report on Monday, December 22nd. Ten analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $13.12.

About Arvinas

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.